JP2020500155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500155A5 JP2020500155A5 JP2019519679A JP2019519679A JP2020500155A5 JP 2020500155 A5 JP2020500155 A5 JP 2020500155A5 JP 2019519679 A JP2019519679 A JP 2019519679A JP 2019519679 A JP2019519679 A JP 2019519679A JP 2020500155 A5 JP2020500155 A5 JP 2020500155A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- skin
- treatment
- cosmetically
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- -1 alicyclyl Chemical group 0.000 claims description 13
- 230000002265 prevention Effects 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 208000035484 Cellulite Diseases 0.000 claims description 8
- 206010049752 Peau d'orange Diseases 0.000 claims description 8
- 230000036232 cellulite Effects 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 238000012423 maintenance Methods 0.000 claims description 8
- 230000009759 skin aging Effects 0.000 claims description 8
- 125000002015 acyclic group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 230000006372 lipid accumulation Effects 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 230000004130 lipolysis Effects 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000037394 skin elasticity Effects 0.000 claims description 4
- 230000036558 skin tension Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 235000007173 Abies balsamea Nutrition 0.000 claims description 2
- 239000004857 Balsam Substances 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 244000018716 Impatiens biflora Species 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000620 organic polymer Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 230000002028 premature Effects 0.000 claims description 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000002669 linoleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102100038815 Nocturnin Human genes 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 108010087192 nocturnin Proteins 0.000 description 2
- 230000003919 adipocyte function Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382466.7 | 2016-10-13 | ||
| EP16382466 | 2016-10-13 | ||
| PCT/US2017/056300 WO2018071640A1 (en) | 2016-10-13 | 2017-10-12 | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020500155A JP2020500155A (ja) | 2020-01-09 |
| JP2020500155A5 true JP2020500155A5 (enExample) | 2020-11-19 |
Family
ID=57153435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519679A Pending JP2020500155A (ja) | 2016-10-13 | 2017-10-12 | 皮膚、毛髪、爪および／または粘膜の処置および／またはケアにおいて有用な化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200046625A1 (enExample) |
| EP (1) | EP3526231A1 (enExample) |
| JP (1) | JP2020500155A (enExample) |
| KR (1) | KR20190067218A (enExample) |
| CN (1) | CN110072875A (enExample) |
| AU (1) | AU2017342344A1 (enExample) |
| BR (1) | BR112019007420A2 (enExample) |
| WO (1) | WO2018071640A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018237218A1 (en) | 2017-06-23 | 2018-12-27 | The Procter & Gamble Company | Composition and method for improving the appearance of skin |
| EP3817717A1 (en) | 2018-07-03 | 2021-05-12 | The Procter & Gamble Company | Method of treating a skin condition |
| EP3921328A1 (en) * | 2019-02-08 | 2021-12-15 | Lubrizol Advanced Materials, Inc. | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes |
| US11529300B2 (en) * | 2019-07-03 | 2022-12-20 | Jamrm, Llc | Formulations for enhancing skin firmness, density and thickness |
| US20210251882A1 (en) * | 2020-02-17 | 2021-08-19 | Mary Kay Inc. | Topical cosmetic compositions |
| JP7590462B2 (ja) | 2020-06-01 | 2024-11-26 | ザ プロクター アンド ギャンブル カンパニー | ビタミンｂ３化合物の皮膚への浸透を改善する方法 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| CN111793116B (zh) * | 2020-07-20 | 2022-03-04 | 广州和佳润颜医药有限公司 | 一种透皮七肽、含有该透皮七肽的美容组合物及制备方法 |
| US20220218584A1 (en) * | 2021-01-13 | 2022-07-14 | Allergan Sales, Llc | Topical composition and method of use |
| EP4536177A2 (en) * | 2021-07-21 | 2025-04-16 | Purvala Bioscience, Inc. | Cysteine reactive peptides |
| GR1010349B (el) * | 2021-09-30 | 2022-12-02 | Σωτηριος Αδαμιδης | Συνθεση κατα της κυτταριτιδας |
| CN118234480A (zh) * | 2021-11-02 | 2024-06-21 | 科蒂公司 | 局部组合物和其用途 |
| CN114601759B (zh) * | 2022-04-01 | 2023-06-27 | 广州研智化妆品有限公司 | 一种具有抗敏、舒缓功效的组合物 |
| CN115054556B (zh) * | 2022-07-29 | 2023-08-01 | 上海新高姿化妆品有限公司 | 一种修护光损伤的组合物及其应用 |
| CN115444965B (zh) * | 2022-08-18 | 2024-03-29 | 南通大学 | 一种环肽抗菌纳米敷料及其制备方法 |
| FR3144506A1 (fr) * | 2022-12-30 | 2024-07-05 | L V M H Recherche | Association d’actifs avec pantetheine s sulfonate pour une action purifiante |
| CN120329382B (zh) * | 2025-06-16 | 2025-10-17 | 黑龙江辛巴赫生物科技有限公司 | 一种多肽及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455303A (en) * | 1983-05-24 | 1984-06-19 | The General Hospital Corporation | Renin inhibitors |
| JPH10182696A (ja) * | 1996-12-27 | 1998-07-07 | Teikoku Seiyaku Co Ltd | ｇｐ１２０に対して親和性を有するペプチド |
| US20040214184A1 (en) * | 2001-02-28 | 2004-10-28 | Skubitz Keith M | Small peptides capable of modulating the function of cd66 (ceacam) family members |
| US20040192611A1 (en) * | 2003-03-28 | 2004-09-30 | Kraft Foods Holdings, Inc. | Peptide antioxidants from soy protein |
| WO2005065686A1 (en) * | 2004-01-07 | 2005-07-21 | Adipogen Pharmaceuticals Pty Limited | Differentiation modulating agents and uses therefor |
| DE102006020382A1 (de) * | 2006-04-28 | 2007-10-31 | Henkel Kgaa | Schnell trocknende kosmetische Emulsionen zur Roll-on-Applikation |
| DE102006053886A1 (de) * | 2006-11-14 | 2008-05-15 | Henkel Kgaa | Rückstandsarmer kosmetischer oder dermatologischer Stift auf Basis einer Öl-in-Wasser-Dispersion/Emulsion III |
| WO2010041150A2 (en) * | 2008-10-10 | 2010-04-15 | Protagonists Ltd. | Pharmaceutical peptides for the treatment of inflammatory diseases |
| DE102008053273A1 (de) * | 2008-10-27 | 2010-04-29 | Henkel Ag & Co. Kgaa | Kosmetische und dermatologische Zusammensetzungen zur dreidimensionalen Reduktion von Falten |
-
2017
- 2017-10-12 BR BR112019007420A patent/BR112019007420A2/pt not_active IP Right Cessation
- 2017-10-12 US US16/341,338 patent/US20200046625A1/en not_active Abandoned
- 2017-10-12 JP JP2019519679A patent/JP2020500155A/ja active Pending
- 2017-10-12 WO PCT/US2017/056300 patent/WO2018071640A1/en not_active Ceased
- 2017-10-12 EP EP17787857.6A patent/EP3526231A1/en not_active Withdrawn
- 2017-10-12 KR KR1020197013607A patent/KR20190067218A/ko not_active Ceased
- 2017-10-12 CN CN201780076580.4A patent/CN110072875A/zh active Pending
- 2017-10-12 AU AU2017342344A patent/AU2017342344A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500155A5 (enExample) | ||
| JP2016519105A5 (enExample) | ||
| JP2019502677A5 (enExample) | ||
| JP2016502550A5 (enExample) | ||
| JP2015514721A5 (enExample) | ||
| US9561255B2 (en) | Cosmetic, external skin preparation, and medical instrument | |
| ES2362301T3 (es) | Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido. | |
| JP2015514124A5 (enExample) | ||
| KR102158165B1 (ko) | 하이드로겔 형성재료, 프리믹스 및 하이드로겔 형성방법 | |
| JP4995155B2 (ja) | 生体コラーゲン合成促進剤並びに生体コラーゲン合成促進用化粧品及び医薬部外品 | |
| ES2668072T3 (es) | Bioactivador metabólico cutáneo | |
| JP2007506767A (ja) | Ｎ−アシル−ｌ−アスパラギン酸を利用した方法および製造物 | |
| JP2011528678A5 (enExample) | ||
| ES2754523T3 (es) | Composiciones estimulantes de células madre | |
| EP2624806B1 (en) | Cosmetic skin care compositions comprising insoluble copper oxide | |
| RU2012118581A (ru) | Пептиды, используемые в лечении и/или наблюдении за кожей, слизистыми оболочками и/или волосами, и их применение в косметических или фармацевтических композициях | |
| JP2015514722A5 (enExample) | ||
| KR20140027967A (ko) | 화장료의 제조방법, 화장료용 겔의 조제방법 및 화장료 원료에 배합되는 고분자 증점제의 사용량을 경감하는 방법 | |
| JPWO2009078366A1 (ja) | α−リポ酸ナノ粒子およびその調製方法 | |
| AU2020418843B2 (en) | PPAR agonist complex and methods of use | |
| CN107787218A (zh) | 液态清凉组合物 | |
| AU2019338459B2 (en) | Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses therefor | |
| AU2019339488B2 (en) | Uses of plasminogen activator inhibitor 1 (PAI-1) inhibitors | |
| JP2009517348A (ja) | 構造的に変性された脂質の輸送／再利用のための蛋白質を含有する調製物及びその適用 | |
| EP3329905A1 (en) | Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin |